Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth. The 1980s saw for the first time the identification, purification, and sequencing of the two prototypic heparin-binding angiogenic fibroblast growth factors (FGF) 1 and 2. Since then, 22 structurally-related members of the FGF family and different classes of FGF receptors have been identified. Several experimental evidences point to a role for various FGFs in the neovascularization process that takes place in inflammation, angioproliferative diseases, and tumor growth. Thus, the FGF/FGF receptor system represents a target for the development of anti-angiogenic therapies. Purpose of this review is to summarize the different modalities that have been approached to impair the pro-angiogenic activity of the FGF/FGF receptor system and discuss their possible therapeutic implications.
Rusnati
M
M
Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Italy.
Presta
M
M
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D015195:Drug Design; D042783:Endothelial Cells / Q000187:drug effects / Q000502:physiology; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors* / Q000502:physiology; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D018919:Neovascularization, Physiologic; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D020533:Angiogenesis Inhibitors; D017468:Receptors, Fibroblast Growth Factor; D005346:Fibroblast Growth Factors